Journal: Breast cancer research and treatment
Article Title: A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
PMID/MRN: 27798749
Publication Date: 2016-Oct-31
Abstract:
The PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line treatment of metastatic breast cancer (MBC).
This randomized, phase III, open-label, multicenter trial enrolled first-line MBC patients who were ineligible for endocrine or trastuzumab therapy. Cumulative adjuvant anthracyclines of 360Êmg/m 2 doxorubicin or equivalent were allowed. Left ventricular ejection fraction ofÊ>50Ê% was required. Patients received PLD 50Êmg/m 2 every 28Êdays or capecitabine 1250Êmg/m 2 twice daily for 14Êdays every 21Êdays. The primary endpoint was time-to-disease progression (TTP).
210 patients were randomized (nÊ=Ê105, PLD and nÊ=Ê105, capecitabine). Adjuvant anthracyclines were given to 37Ê% (PLD) and 36Ê% (capecitabine) of patients. No significant difference was observed in TTP [HRÊ=Ê1.21 (95Ê% confidence interval, 0.838-1.750)]. Median TTP was 6.0Êmonths for both PLD and capecitabine. Comparing patients with or without prior anthracyclines, no significant difference in TTP was observed in the PLD arm (log-rank PÊ=Ê0.64). For PLD versus capecitabine, respectively, overall survival (median, 23.3Êmonths vs. 26.8Êmonths) and time-to-treatment failure (median, 4.6Êmonths vs. 3.7Êmonths) were not statistically significantly different. Compared to PLD, patients on capecitabine experienced more serious adverse events (PÊ=Ê0.015) and more cardiac events among patients who had prior anthracycline exposure (18 vs. 8Ê%; PÊ=Ê0.31).
Both PLD and capecitabine are effective first-line agents for MBC.